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Population-based studies have investigated the relation between β-amyloid levels in cerebrospinal fluid or plasma and white matter
lesions (WMLs). However, these circulating levels of β-amyloid in cerebrospinal fluid or plasma may not reliably reflect the actual
degree of amyloid present in the brain. Therefore, we investigated the relation between WMLs and β-amyloid plaques and amyloid
angiopathy in brain tissue. WML onMRI or CT were rated in 28 nondemented patients whose neuroimaging was available prior to
death. β-amyloid in plaques and arterioles were immunohistochemically stained and quantified in postmortem brain necropsies.
WMLs were present in 43% of the total population. Both cortex and periventricular region showed no diﬀerences for β-amyloid
deposition in either plaques or blood vessel walls in patients with WMLs compared to those without WMLs. Thus, our results
indicate that there is no relation between the degree of WMLs and β-amyloid deposition in the brain.
1. Introduction
Cerebral white matter lesions (WMLs) are commonly found
on cerebral magnetic resonance imaging (MRI) and comput-
erized tomography (CT) in elderly subjects [1, 2]. The fre-
quency ofWML increases with age [3], and they are related to
both cognitive impairment [4] and Alzheimer’s disease (AD)
[5].
From an etiological perspective, heterogeneity exists with
respect to the presence of WML: on the one hand, they are
related to cardiovascular risk factors, including hypertension
and atherosclerosis [6–8], but on the other hand, they are
abundantly present in patients with an underlying amyloid
pathology such as cerebral amyloid angiopathy (CAA) [9].
On a population level, there is also evidence for such
heterogeneity since a relation between WMLs on MRI and
levels of β-amyloid in cerebrospinal fluid or plasma has
been established [3, 10]. However, a recent study did not
find any association between β-amyloid in cerebrospinal
fluid and WML [11]. Furthermore, there is no confirmation
of β-amyloid pathology in brain tissue in these particular
studies. There are a few neuropathological studies which en-
countered a relation between the degree of CAA, β-amyl-
oid plaques, and the severity of WML in patients with clin-
ically confirmed AD, albeit that both the amyloid and white
matter pathology were assessed on a microscopic level and
not with neuroimaging [12, 13].
To investigate the relation between cerebral amyloid
pathology within white matter lesions and the degree of
white matter lesions on neuroimaging, one should preferably
look for amyloid pathology in a sample of the white matter.
This may have important implications for our understanding
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of the etiology and found heterogeneity of presumed vascular
white matter lesions and provide a model for interaction
between vascular and amyloid pathology in the pathophys-
iology of WMLs. To our best knowledge, there are no stud-
ies relating the presence of WMLs on neuroimaging with
neuropathologically assessed amyloid pathology.
We therefore investigated the relation between the degree
of β-amyloid deposition in microvessels and plaques in ne-
cropsies from the cerebral white matter and WMLs and
WMLs assessed onMRI in an autopsy-based study of nonde-
mented patients.
2. Materials and Methods
2.1. Study Population. The study population consisted of 28
consecutive patients without any age restriction from whom
neuroimaging was available on average 2.8 months prior to
death. No significant diﬀerence exists in time of imaging
prior to death between theWMLs groups. Neuroimaging was
performed for routine investigations because of a suspicion
of a neurological disorder not related to dementia (minor
stroke, minor traumatic brain injury, and exclusion of brain
tumor). None of the patients suﬀered from dementia accord-
ing to NINDS-AIREN [14] and NINCDS-ADRDA [15] crite-
ria and all of them died of noncerebral or nonneurodegener-
ative causes. Autopsy consent was obtained from the next of
kin. The study was approved by the Medical Ethics Commit-
tee of University Medical Center Utrecht, the Netherlands.
2.2. Tissue Samples. Within 16 hours after death, necropsies
were taken from the frontal lobe region of the hemisphere
which was predominantly aﬀected by the WMLs. When
trauma or stroke occurred in this hemisphere, the necropsy
was taken from the other, unaﬀected hemisphere. Samples,
each about 2 cm3 in size, were taken from the frontal
grey matter and the underlying periventricular region in a
standardized way, guided by the obtained CT or MRI scan.
The periventricular region was defined as the region from the
ventricle wall extending 1 cm into the white matter.
Tissue was fixed in 4% paraformaldehyde in 0.1M phos-
phate buﬀer (pH 7.4) and embedded in paraﬃn according to
a standard protocol.
2.3. β-Amyloid Immunohistochemistry. β-amyloid was dem-
onstrated immunohistochemically on 4 μm thin paraﬃn sec-
tions using monoclonal antibodies against the βA4-amyloid
(1 : 100; clone 6F/3D, DAKO M0872, Glostrup, Denmark).
To determine the amount of β-amyloid, sections were di-
gitalized and quantified, using a Zeiss Axioskop microscope
equipped with hardware and software of Microbright-
field, (Williston, USA). Quantitative analyses were perform-
ed with a computer-assisted analysis system (Stereo Inves-
tigator) using Cavalieri’s probe. Total β-amyloid staining
in both plaques and cerebral blood vessel walls was meas-
ured by two independent raters in a random 25 × 106 μm2
cortex and periventricular white matter area. The β-amyloid
deposition in plaques was expressed as the area of β-amyloid
positive plaques divided by the total area measured, times
100 in order to obtain a percentage of the aﬀected area. Sub-
sequently, β-amyloid deposition in cerebral blood vessels
was quantified in a similar manner. Immunohistochemistry
and determination of β-amyloid positivity was measured
without knowledge of rating of the WMLs or any other clin-
ical data.
2.4. Rating of White Matter Lesions. WMLs were rated with
the age-related white matter changes (ARWMCs) rating scale
by one single experienced rater (FEdL) [16]. The use of this
rating scale has the advantage that it can be used for rating
WMLs on both CT and MRI with high inter- and intra-
rater agreement. In short, WMLs were defined as ill-defined
hyperintensities ≥5mm on MRI images or as ill-defined and
moderately hypodense areas of ≥5mm on CT images. They
were rated on a four-point scale in five diﬀerent regions
in the left and right hemisphere separately: (1) the frontal
area, (2) the parieto-occipital area, (3) the temporal area,
(4) the infratentorial area, and (5) the basal ganglia. WMLs
were scored semiquantitatively as 0 (no WMLs), 1 (single or
multiple focal lesions≥5mm), 2 (beginning of confluence of
lesions) or 3 (confluent WMLs).
Total degree of WMLs was calculated by adding the re-
gion-specific scores of both hemispheres (range 0–30).
2.5. Statistical Analysis. We compared the β-amyloid load
in plaques and in cerebral blood vessels in patients with
WMLs (ARWMC> 0) or withoutWMLs (ARWMC = 0) with
the Mann-Whitney U test because of a nonparametric dis-
tribution of the amyloid deposition. To identify diﬀerences
in population characteristics between groups, the Mann-
Whitney U test and Chi-square test were used.
To assess whether any observed diﬀerences were influ-
enced by age, partial Spearman’s correlations were calculated
betweenWMLs and β-amyloid, adjusting for age and gender.
3. Results
Table 1 shows the characteristics of the study population.
Mean age was 63.1 yrs (SD 15.9 yrs; range 18–84 yrs); 39%
was female. WMLs were present in 43% of the total pop-
ulation. Mean coverage of the area by β-amyloid plaques was
0.08% (range 0.0 to 1.02%) in the cortex and 0.0003% (range
0.0 to 0.003%) in the periventricular white matter region.
Mean coverage of the area by vascular amyloid was 0.005%
(range 0.0 to 0.040%) in the cortex, with no amyloid found
in vessels in the periventricular white matter.
Patients with WMLs had significantly more cortical β-
amyloid plaques than those withoutWMLs (0.17% (SD 0.33)
versus 0.01% (SD 0.03); P < 0.05, Figure 1). However, both
groups diﬀered in age (Table 1). Therefore, we assessed the
influence of age on a possible correlation between cortical
β-amyloid coverage and WMLs. After adjusting by age,
no correlation could be found between cortical β-amyloid
coverage and WMLs (crude Spearman’s Rho correlation
coeﬃcient = 0.41, P < 0.05, age-adjusted correlation
coeﬃcient = 0.17, P = 0.40).
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Figure 1: (a) MRI scans with and without white matter lesions and (b) corresponding β-amyloid pathology in the cortex. Bar = 100 μm.
Table 1: Characteristics of the study population.
Total
(n = 28)
no WMLs
(n = 16)
WMLs
(n = 12)
Age, years 63.1 (15.9) 56.8 (13.6) 71.6 (15.3)#
Women, % 39.3 18.8 66.7∗
Hypertension, % 46.2 33.3 63.6
Diabetes mellitus, % 11.1 13.3 8.3
Cerebral infarct, % 15.4 14.3 16.7
Myocardial infarction, % 7.4 6.7 8.3
Median ARWMC 0 0 8
Ventricle-to-brain ratio 0.36 (0.06) 0.36 (0.06) 0.36 (0.05)
Values are unadjusted means (SD) or percentages.
∗#Mean or percentage is significantly diﬀerent from people with no WMLs,
P < 0.05 and P < 0.01, respectively.
The amount of β-amyloid plaques in the periventricular
area and vascular amyloid in both the cortical and periven-
tricular area did not diﬀer between the WMLs groups also
not after adjustment for age and gender.
4. Discussion
We found no association between WMLs and β-amyloid de-
position in the brain of elderly nondemented persons.
To our best knowledge, this study is the first to investigate
a possible relation between amyloid pathology and the pres-
ence of WMLs on MRI in nondemented elderly by directly
assessing the load of β-amyloid in the brain, rather than an
indirect measure of amyloid pathology (cerebral spinal fluid
or plasma levels).
In accordance with a recent study by Jonsson et al. [11],
our results do not indicate that β-amyloid and WMLs are
related.
Our results are not completely in agreement with a study
by Stenset et al. [10]. They investigated whether WMLs
lesions were inversely related with CSF Aβ42, following the
rationale that CSF Aβ42 reduction is seen in AD due to
deposition in β-amyloid plaques. They found that WMLs
and hypercholesterolemia explained only 9% of the variabil-
ity in CSF Aβ42, suggesting that other factors must play
a role in the development of white matter lesions. Having
hypercholesterolemia raised the probability of low Aβ42
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levels by 20%, while for each point increase in WMLs score
(same scale as used in our study), the probability of low
CSF Aβ42 levels only increased by 3%. In contrast to our
findings, Aβ42 levels did not correlate with age. However,
it remains controversial whether amyloid markers either in
CSF or blood plasma reflect actual amyloid pathology in the
brain [17–19].
A possible weakness of our study was the small number
of patients. Since not even a trend towards a relation between
amyloid pathology in the brain and WMLs on neuroimaging
could be detected in our sample, we expect this relation to be
weak, especially compared to the strength of the association
with other common factors like age. However, one has to
keep in mind that a type II error may have lead to false neg-
ative findings in our study.
Neuroimaging was performed on average 3 months prior
to death. WMLs might have progressed in this limited time
interval, but this is very unlikely, as the progression rate of
WMLs is known to be very slow [3, 20].
Theoretically, staining of the tissuemight vary by reduced
immunoreactivity due to diﬀerent postmortem times, but
in this study, there were no diﬀerences in postmortem time
between groups (data not shown).
Before clinical signs of AD are perceptible, both WMLs
assessed on MRI and β-amyloid plaques in the cortex are
already present [1, 21] and increase with age. The presence
of white matter lesions in AD is often seen; moreover, these
WMLs and AD share some risk factors, wit hage being the
most important. Consequently, coexisting WMLs and AD
results in more severe cognitive impairment, either by direct
damage of the neural pathway, or indirect by worsening the
impact of AD pathology [22].
As hypothesized by others, this suggests that cerebrovas-
cular disease may be in the causal pathway for development
of AD or interacts synergistically with AD pathology.
The presence of β-amyloid plaques has been considered
the defining characteristic of AD, and it forms the core of
the most studied theoretical framework for AD: the amyloid
cascade hypothesis [23].
On the other hand, WMLs might be more supportive of
the vascular hypothesis [24, 25]. WMLs are thought to have
a vascular origin, because vascular risk factors, especially
hypertension, are related to the presence of these lesions [8].
Furthermore, evidence suggests that white matter is highly
vulnerable to hypoxia due to vascular dysfunction [26, 27].
In the last decade, several large population-based studies
have highlighted the important contribution of vascular risk
factors in AD [28–30].
As a result, some researchers are in favor of the amyloid
cascade hypothesis, while others believe in the vascular hy-
pothesis. However, the association between vascular risk fac-
tors and AD does not rule out degenerative mechanisms
underlying pure AD. It can be hypothesized that vascular and
degenerative mechanisms actually develop in parallel. Vas-
cular brain injury could act additively or synergistically with
concomitant
AD pathology to produce more severe cognitive dysfunc-
tion than either process alone [31].
To conclude, our results show no association between
WMLs and β-amyloid load in the brain of elderly nonde-
mented persons. Although they might have causal factors
in common, WMLs and β-amyloid load in the brain could
represent separate pathways to AD.
Further research is necessary to clarify these complex
relationships. Prospective, multimodal imaging studies in
disease-free individuals that both visualize the degree of
amyloid pathology (e.g., with PET-PIB) [32] and the degree
of WMLs are needed to unravel the chain of events from
amyloid pathology and white matter lesions and the atten-
dant cognitive decline [33].
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